Dimebon
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Huntington Disease
Conditions
Huntington Disease
Trial Timeline
Jul 1, 2009 → —
NCT ID
NCT00920946About Dimebon
Dimebon is a phase 3 stage product being developed by Pfizer for Huntington Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00920946. Target conditions include Huntington Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01152216 | Phase 3 | Terminated |
| NCT00939783 | Phase 3 | Terminated |
| NCT00920946 | Phase 3 | Completed |
Competing Products
20 competing products in Huntington Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + Matching Placebo | Eli Lilly | Phase 2 | 52 |
| Votoplam (blinded) + Placebo | Novartis | Phase 3 | 77 |
| Votoplam | Novartis | Phase 2 | 52 |
| Branaplam + Placebo | Novartis | Phase 2 | 52 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| RO7234292 (RG6042) | Roche | Phase 1 | 33 |
| Tominersen + Placebo | Roche | Phase 2 | 52 |
| RO7234292 (RG6042) | Roche | Phase 3 | 77 |
| RO7234292 (RG6042) | Roche | Phase 2 | 52 |
| RG6496 + Placebo | Roche | Phase 1 | 33 |
| RO7234292 + Placebo | Roche | Phase 3 | 77 |
| PF-02545920 + PF-02545920 | Pfizer | Phase 2 | 51 |
| Dextromethorphan + Dimebon + Dextromethorphan | Pfizer | Phase 1 | 32 |
| Dimebon (latrepirdine) | Pfizer | Phase 3 | 76 |
| 20 mg BID of PF-02545920 | Pfizer | Phase 2 | 51 |
| PF-02545920 + Placebo + PF-02545920 + Placebo | Pfizer | Phase 2 | 51 |
| Riluzole | Sanofi | Phase 3 | 76 |
| ALN-HTT02 + Placebo | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Tetrabenazine | Lundbeck | Approved | 82 |
| Valbenazine | Neurocrine Biosciences | Phase 3 | 74 |